Cargando…

Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil

BACKGROUND: The use of atypical antipsychotics for the treatment of schizophrenia and other mental disorders in populations under 18 years of age is increasing worldwide. Little is known about treatment patterns and the influence of gender differences, which may be a predictor of clinical outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Fulone, Izabela, Silva, Marcus Tolentino, Lopes, Luciane Cruz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243572/
https://www.ncbi.nlm.nih.gov/pubmed/34187418
http://dx.doi.org/10.1186/s12888-021-03327-7
_version_ 1783715775268257792
author Fulone, Izabela
Silva, Marcus Tolentino
Lopes, Luciane Cruz
author_facet Fulone, Izabela
Silva, Marcus Tolentino
Lopes, Luciane Cruz
author_sort Fulone, Izabela
collection PubMed
description BACKGROUND: The use of atypical antipsychotics for the treatment of schizophrenia and other mental disorders in populations under 18 years of age is increasing worldwide. Little is known about treatment patterns and the influence of gender differences, which may be a predictor of clinical outcomes. The aim of this study was to investigate gender differences in the use of atypical antipsychotics in patients with early-onset schizophrenia (EOS) assisted by the public health system in Brazil. METHODS: We conducted a cross-sectional study of outpatients with EOS aged 10 to 17 years who received at least one provision of atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine or ziprasidone) from a large Brazilian pharmaceutical assistance programme. Data were retrieved from a nationwide administrative database from 2008 to 2017. RESULTS: Of the 49,943 patients with EOS, 63.5% were males, and the mean age was 13.6 years old. The patients were using risperidone (62.5%), olanzapine (19.6%), quetiapine (12.4%), ziprasidone (3.3%) and clozapine (2.2%). We found gender differences, especially in the 13–17 year age group (65.1% for males vs. 34.9% for females, p < 0.001), in the use of risperidone (72.1% for males vs. 27.9% for females, p < 0.001) and olanzapine (66.5% for males vs. 33.5% for females, p < 0.001). Only in the 13 to 17 years age group were the prescribed doses of olanzapine (p = 0.012) and quetiapine (p = 0.041) slightly higher for males than for females. CONCLUSIONS: Our findings showed gender differences among patients diagnosed with EOS and who received atypical antipsychotics. More attention should be devoted to gender differences in research and clinical practice.
format Online
Article
Text
id pubmed-8243572
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82435722021-06-30 Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil Fulone, Izabela Silva, Marcus Tolentino Lopes, Luciane Cruz BMC Psychiatry Research Article BACKGROUND: The use of atypical antipsychotics for the treatment of schizophrenia and other mental disorders in populations under 18 years of age is increasing worldwide. Little is known about treatment patterns and the influence of gender differences, which may be a predictor of clinical outcomes. The aim of this study was to investigate gender differences in the use of atypical antipsychotics in patients with early-onset schizophrenia (EOS) assisted by the public health system in Brazil. METHODS: We conducted a cross-sectional study of outpatients with EOS aged 10 to 17 years who received at least one provision of atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine or ziprasidone) from a large Brazilian pharmaceutical assistance programme. Data were retrieved from a nationwide administrative database from 2008 to 2017. RESULTS: Of the 49,943 patients with EOS, 63.5% were males, and the mean age was 13.6 years old. The patients were using risperidone (62.5%), olanzapine (19.6%), quetiapine (12.4%), ziprasidone (3.3%) and clozapine (2.2%). We found gender differences, especially in the 13–17 year age group (65.1% for males vs. 34.9% for females, p < 0.001), in the use of risperidone (72.1% for males vs. 27.9% for females, p < 0.001) and olanzapine (66.5% for males vs. 33.5% for females, p < 0.001). Only in the 13 to 17 years age group were the prescribed doses of olanzapine (p = 0.012) and quetiapine (p = 0.041) slightly higher for males than for females. CONCLUSIONS: Our findings showed gender differences among patients diagnosed with EOS and who received atypical antipsychotics. More attention should be devoted to gender differences in research and clinical practice. BioMed Central 2021-06-29 /pmc/articles/PMC8243572/ /pubmed/34187418 http://dx.doi.org/10.1186/s12888-021-03327-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Fulone, Izabela
Silva, Marcus Tolentino
Lopes, Luciane Cruz
Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
title Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
title_full Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
title_fullStr Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
title_full_unstemmed Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
title_short Gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in Brazil
title_sort gender differences in the use of atypical antipsychotics in early-onset schizophrenia: a nationwide population-based study in brazil
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243572/
https://www.ncbi.nlm.nih.gov/pubmed/34187418
http://dx.doi.org/10.1186/s12888-021-03327-7
work_keys_str_mv AT fuloneizabela genderdifferencesintheuseofatypicalantipsychoticsinearlyonsetschizophreniaanationwidepopulationbasedstudyinbrazil
AT silvamarcustolentino genderdifferencesintheuseofatypicalantipsychoticsinearlyonsetschizophreniaanationwidepopulationbasedstudyinbrazil
AT lopeslucianecruz genderdifferencesintheuseofatypicalantipsychoticsinearlyonsetschizophreniaanationwidepopulationbasedstudyinbrazil